Iron Bioavailability From Dairy Product

Société des Produits Nestlé (SPN)20 enrolled

Overview

Determination of fractional iron absorption from dairy product fortified with 2 labelled iron compounds

This single center trial will be double-blind, controlled randomized with a crossover trial. One group (n=10) will start the study with the consumption of a Fe-54 salt fortified dairy product, while the other group will start the study with the consumption of Fe-57 salt fortified dairy product. The day after, in a cross over design, subjects will be administered the alternative test product. A blood sampling will be performed 14 days after the last stable isotope administration to allow the measurement of Fe stable isotope ratios and the calculation of Fe absorption. The duration of the trial will be 16 days in total. The total sample size is 20 enrolled subjects. Patients will be healthy females aged 18-40 years old

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

QUADRUPLE

Enrollment

Conditions

Healthy Volunteers

Interventions

Dairy product fortified with enriched Fe-54 salt (1)DIETARY_SUPPLEMENT

2.5mg of Fe per 100g of product

Dairy product fortified with enriched Fe-57 salt (2)DIETARY_SUPPLEMENT

2.5mg of Fe per 100g of product

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Women aged 18-40 years old, * Healthy, based on the medical screening visit including a blood formula and biochemistry, * Normal BMI for age (18.5-25.0), * Weight less than 65 kg, * Having obtained informed consent prior trial entry. Exclusion Criteria: * Anemia or polycythemia respectively evidenced, * Significant blood losses over the past 6 months, * Plasma ferritin out of 8-50 ug/L range. * Any infectious and inflammatory disease in the past four weeks, * Relevant digestive (intestinal, gastric, hepatic or pancreatic), renal, metabolic disease, * Known food allergy, * Pregnancy (anamnesis) and/or lactation, * History of cancer within the past year, * Significant weight loss during the last 3 months (5% and more), * medication or supplement which may impact red cells count, Hb or Ht * Fe supplementation or perfusion in the last three months, * Smokers (\>5 cigarettes), * Have a high alcohol consumption (more than 2 drinks/day), * Consumption of illicit drugs anamnesis only, * Subject having a hierarchical link with the Investigator or co-investigators, * Subject who cannot be expected to comply with treatment or study procedure, * participating or having participated in another clinical trial during the past month prior to the beginning of this study.

Locations (1)

Metabolic Unit, Clinical Development Unit, Nestec

Lausanne, Switzerland

Outcomes

Primary Outcomes

Change from baseline in the isotopic ratio of iron in blood at week 2

The change in the isotopic ratio of iron will be measured after the administration of test meal including iron isotopes

Time frame: 14 days after the last stable isotope administration

Secondary Outcomes

Measurement of plasma ferritin as biomarker of Fe status

The plasma ferritin will be measured before the administration of test meal including iron isotopes

Time frame: On the 1st day of the stable isotope administration

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.